Cited 3 times in
In vivo application of base and prime editing to treat inherited retinal diseases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김형범 | - |
dc.date.accessioned | 2023-07-12T03:09:34Z | - |
dc.date.available | 2023-07-12T03:09:34Z | - |
dc.date.issued | 2023-05 | - |
dc.identifier.issn | 1350-9462 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195525 | - |
dc.description.abstract | Inherited retinal diseases (IRDs) are vision-threatening retinal disorders caused by pathogenic variants of genes related to visual functions. Genomic analyses in patients with IRDs have revealed pathogenic variants which affect vision. However, treatment options for IRDs are limited to nutritional supplements regardless of genetic variants or gene-targeting approaches based on antisense oligonucleotides and adeno-associated virus vectors limited to targeting few genes. Genome editing, particularly that involving clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 technologies, can correct pathogenic variants and provide additional treat-ment opportunities. Recently developed base and prime editing platforms based on CRISPR-Cas9 technologies are promising for therapeutic genome editing because they do not employ double-stranded breaks (DSBs), which are associated with P53 activation, large deletions, and chromosomal translocations. Instead, using attached deaminases and reverse transcriptases, base and prime editing efficiently induces specific base substitutions and intended genetic changes (substitutions, deletions, or insertions), respectively, without DSBs. In this review, we will discuss the recent in vivo application of CRISPR-Cas9 technologies, focusing on base and prime editing, in animal models of IRDs. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Pergamon | - |
dc.relation.isPartOf | PROGRESS IN RETINAL AND EYE RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | CRISPR-Cas Systems* / genetics | - |
dc.subject.MESH | Gene Editing | - |
dc.subject.MESH | Genome | - |
dc.subject.MESH | Retinal Diseases* / genetics | - |
dc.subject.MESH | Retinal Diseases* / therapy | - |
dc.title | In vivo application of base and prime editing to treat inherited retinal diseases | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pharmacology (약리학교실) | - |
dc.contributor.googleauthor | Dong Hyun Jo | - |
dc.contributor.googleauthor | Sangsu Bae | - |
dc.contributor.googleauthor | Hyongbum Henry Kim | - |
dc.contributor.googleauthor | Jin-Soo Kim | - |
dc.contributor.googleauthor | Jeong Hun Kim | - |
dc.identifier.doi | 10.1016/j.preteyeres.2022.101132 | - |
dc.contributor.localId | A01148 | - |
dc.relation.journalcode | J02895 | - |
dc.identifier.eissn | 1873-1635 | - |
dc.identifier.pmid | 36241547 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1350946222000921 | - |
dc.subject.keyword | Base editing | - |
dc.subject.keyword | CRISPR | - |
dc.subject.keyword | Genetic variant | - |
dc.subject.keyword | Inherited retinal disease | - |
dc.subject.keyword | Prime editing | - |
dc.contributor.alternativeName | Kim, Hyongbum | - |
dc.contributor.affiliatedAuthor | 김형범 | - |
dc.citation.volume | 94 | - |
dc.citation.startPage | 101132 | - |
dc.identifier.bibliographicCitation | PROGRESS IN RETINAL AND EYE RESEARCH, Vol.94 : 101132, 2023-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.